COVID-19 Induced Telogen Effluvium

• Sponsor: Istanbul Medeniyet University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT04834102
• Collaborator: (none)
• Enrollment: 200
• Location: 1
• Anticipated Duration (Months): 3
• Patients Per Site Per Month: 67.6

Study Details

Study Description

Brief Summary

This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection

Condition or Disease	Intervention/Treatment	Phase
Covid19; Telogen Effluvium; SARS-CoV Infection; Alopecia	Diagnostic Test: Blood Tests

Detailed Description

Telogen effluvium (TE) is one of the most common causes of non-scarring alopecia. During the COVİD-19 pandemic, there is an increased number of Telogen effluvium patients.This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection and correlation between the severity of covid-19 and TE.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 200 participants
• Observational Model: Other
• Time Perspective: Retrospective
• Official Title: COVID-19 Induced Telogen Effluvium
• Actual Study Start Date: Jan 27, 2021
• Anticipated Primary Completion Date: Apr 27, 2021
• Anticipated Study Completion Date: Apr 27, 2021

Outcome Measures

Primary Outcome Measures

1. Hair shedding [3 months]

   Physical examination of hair and scalp, trichoscopy, hair pull test

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Sars-CoV-2 infection in the past year

Exclusion Criteria:

• Other common causes of Telogen effluvium ( such as anemia, iron deficiency, thyroid dysfunction)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Istanbul Medeniyet University	Istanbul	Kadıköy	Turkey	34720

Sponsors and Collaborators

• Istanbul Medeniyet University

Investigators

• Principal Investigator: Hasan AKSOY, Dr., Istanbul Medeniyet University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hasan Aksoy, Specialist Dr., Istanbul Medeniyet University
• ClinicalTrials.gov Identifier: NCT04834102
• Other Study ID Numbers: 2021/0123
• First Posted: Apr 6, 2021
• Last Update Posted: Apr 6, 2021
• Last Verified: Apr 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Hasan Aksoy, Specialist Dr., Istanbul Medeniyet University: Telogen Effluvium; Covid-19; Alopecia
• Additional relevant MeSH terms: COVID-19; Severe Acute Respiratory Syndrome; Alopecia; Alopecia Areata

Study Results

No Results Posted as of Apr 6, 2021